Myelofibrosis Therapeutics Market

Each year, approximately 3.6 million people in the United States complain of Lower back pain (LBP). Among all types of chronic pain, back pain has often been suggested to be the most frequent type and is considered the second most common neurologic disease and most physician visits can be attributed to it. The lowe...

Myasthenia gravis (MG) is an autoimmune syndrome that causes weakness in the skeletal muscles caused due to the failure of neuromuscular transmission. Communication between nerve cells and muscles becomes hampered, thus preventing crucial muscles from contracting. This impairment in results from the binding of auto...

Pompe disease is an inherited rare disease, often fatal with a potential to damage heart, liver and skeletal muscles. Absence of an essential protein, Due to the mutation in a gene encoding GAA, there is an absence of a critical protein leading to a complex buildup of sugar, hence, damaging heart, liver and other o...

The global Pompe disease market will experience a boost during the study period of 2019-28. Pompe disease is a rare inheritable disorder with a combined Pompe disease prevalence of 1 in 40,000, affecting males and females equally. The Pompe disease therapeutic market revolves around pharmacological treatment (wh...

The era, we are living in has experienced many advancements in the healthcare system. Curative, and life-changing gene therapies have started to promise a future free of prolonged illness, possessing an ability to treat, cure or ease the life-draining diseases. In a major event, the approval of the other gene t...

An orphan disease is any disease that affects only a small percentage of the population. There can be as many as 7,000 rare diseases known to affect human life. The total number of Americans living with a rare disease is estimated at between 25-30 million. When it comes to the EU, all together, rare disease patient...